147 related articles for article (PubMed ID: 37005131)
21. Management of Fibrosing Interstitial Lung Diseases.
Maher TM; Wuyts W
Adv Ther; 2019 Jul; 36(7):1518-1531. PubMed ID: 31119691
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis.
Molina-Molina M; Buendia-Roldan I; Castillo D; Caro F; Valenzuela C; Selman M
Arch Bronconeumol; 2022 May; 58(5):418-424. PubMed ID: 35312511
[TBL] [Abstract][Full Text] [Related]
24. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
25. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
26. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
Sarkar P; Avram C; Chaudhuri N
Expert Rev Respir Med; 2020 Oct; 14(10):1001-1008. PubMed ID: 32567402
[TBL] [Abstract][Full Text] [Related]
27. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.
Khanna SA; Nance JW; Suliman SA
Curr Rheumatol Rep; 2022 May; 24(5):166-173. PubMed ID: 35499699
[TBL] [Abstract][Full Text] [Related]
28. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
Chartrand S; Lee JS; Swigris JJ; Stanchev L; Fischer A
Lung; 2019 Dec; 197(6):709-713. PubMed ID: 31583453
[TBL] [Abstract][Full Text] [Related]
29. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
30. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
[TBL] [Abstract][Full Text] [Related]
31. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease.
Takei R; Arita M; Kumagai S; Ito Y; Tokioka F; Koyama T; Saito R; Nishimura K; Tokumasu H; Ishida T
Respirology; 2018 Apr; 23(4):385-391. PubMed ID: 28925574
[TBL] [Abstract][Full Text] [Related]
32. [Management of Interstitial Lung Diseases (ILD) Associated with Autoimmune Diseases by the Pulmonologyst in the Differents ILD Units in Spain].
Acosta Fernández O; Aburto Barrenetxea M; Llanos González AB; Rodríguez Nieto MJ; Molina Molina M; Valenzuela C
Open Respir Arch; 2022; 4(1):100160. PubMed ID: 37497172
[TBL] [Abstract][Full Text] [Related]
33. Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases.
Chiu YH; Spierings J; de Jong PA; Hoesein FM; Grutters JC; van Laar JM; Voortman M
Respir Med; 2021 Oct; 187():106579. PubMed ID: 34438351
[TBL] [Abstract][Full Text] [Related]
34. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
35. Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases.
Enomoto N; Naoi H; Mochizuka Y; Isayama T; Tanaka Y; Fukada A; Aono Y; Katsumata M; Yasui H; Mori K; Karayama M; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T
BMC Pulm Med; 2022 Oct; 22(1):387. PubMed ID: 36289542
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies.
Diesler R; Cottin V
Expert Rev Respir Med; 2022 May; 16(5):541-553. PubMed ID: 35695895
[TBL] [Abstract][Full Text] [Related]
37. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
Nili M; Singer D; Hanna M
BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
[TBL] [Abstract][Full Text] [Related]
38. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
39. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
[TBL] [Abstract][Full Text] [Related]
40. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
